Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient

Cutis

Volumn 99, Issue 2, 2017, Pages E30-E34

  Eshagh, Karin ^a   Romero, Laura Sullivan ^b,c   Kim So, Jessica ^d   Zhao, Xianfeng Frank ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b San Diego   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d SHARP HEALTHCARE   (United States)

^e Phoenix VA Healthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEXAROTENE; TETRALIN DERIVATIVE;

CASE REPORT; CD4+ T LYMPHOCYTE; CHEMICALLY INDUCED; HUMAN; IMMUNOLOGY; LYMPHOCYTOPENIA; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; TIME FACTOR;

ANTICARCINOGENIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; LYMPHOPENIA; MALE; MIDDLE AGED; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES; TIME FACTORS;

EID: 85014841096     PISSN: 00114162     EISSN: 23266929     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. + T-lymphocytopenia Task Force. N Engl J Med. 1993;328:373-379.
2. Castelino DJ, McNair P, Kay TW. Lymphocytopenia in a hospital population: what does it signify? Aust N Z J Med. 1997;27:170-174.
3. + lymphocytopenia: natural history and prognostic factors. Blood. 2008;112:287-294.
4. + T-lymphocytopenia: four patients with opportunistic infections and no evidence of HIV infection. N Engl J Med. 1993;328:393-398.
5. Bruno NP, Beacham BE, Burnett JW. Adverse effects of isotretinoin therapy. Cutis. 1984;33:484-486, 489.
6. Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 1984;10:490-496.
7. Windhorst DB, Nigra T. General clinical toxicology of oral retinoids. J Am Acad Dermatol.1982;6:675-682.
8. Glinnick SE. Leucopenia from accutane: in ten percent? Schoch Let. 1985;35:9.
9. Wilcox RA. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:928-948.
10. Nieto-Rementería N, Pérez-Yarza G, Boyano MD, et al. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009;160:519-526.
11. Richardson SK, Newton SB, Bach TL, et al. Bexarotene blunts malignant T-cell chemotaxis in Sézary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. Am J Hematol. 2007;82:792-797.
12. Bouwhuis SA, Davis MD, el-Azhary RA, et al. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients. J Am Acad Dermatol. 2005;52:991-996.
13. Targretin [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals International, Inc; 2015.
14. Abbott RA, Whittaker SJ, Morris SL, et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol. 2009;160:1299-1307.
15. Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002;47:672-684.
16. Scarisbrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013;168:192-200.
17. Black E, Lau TT, Ensom MH. Vancomycin-induced neutropenia: is it dose-or duration related? Ann Pharmacother. 2011;45:629-638.
18. Choo PW, Gantz NM. Reversible leukopenia related to ciprofloxacin therapy. South Med J. 1990;83:597-598.
19. + T lymphocytopenia in a patient with mycosis fungoides. J Am Acad Dermatol. 1995;32:1063-1064.